David Lancaster


Senior Associate (Barrister)

David has experience in all aspects of contentious intellectual property law, including patents, trade marks, copyright, registered and unregistered designs, passing off and confidential information. He has a background in biochemistry and has particular experience in the life sciences sector. He also represents clients in the telecommunications sector, including in proceedings for determination of fair, reasonable and non-discriminatory (FRAND) licence terms.

David has experience of handling multi-jurisdictional patent actions, EPO oppositions and arbitrations. He also has rights of audience in all courts, having trained and qualified as a barrister, and has represented clients as the advocate in the High Court, the UK IPO and before the Opposition Division of the EPO.

David joined Powell Gilbert in 2012.

Key cases

  • Samsung Bioepis & Biogen v AbbVie (adalimumab) 

  • GlaxoSmithKline Biologicals v UCB Pharma (vaccines)

  • Icahn School of Medicine at Mount Sinai (SPCs - agalsidase beta)

  • Vringo v ZTE (telecommunications/FRAND licensing)

  • Sony v SSH (computer networks)

  • Rovi v Virgin Media & TiVo (electronics)

  • Eugen Seitz v KHS Corpoplast & Norgren (PET plastic technology)

  • Eli Lilly v Human Genome Sciences (SPCs – neutrokine alpha)

  • GlaxoSmithKline Biologicals v Novartis (meningococcal vaccines)